Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
8.52
+0.01 (0.10%)
Aug 14, 2025, 11:24 AM - Market open
Y-mAbs Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover Y-mAbs Therapeutics stock have a consensus rating of "Buy" and an average price target of $15.02, which forecasts a 76.32% increase in the stock price over the next year. The lowest target is $7.00 and the highest is $25.
Price Target: $15.02 (+76.32%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Y-mAbs Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 4 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $11 → $8.6 | Strong Buy → Hold | Downgrades | $11 → $8.6 | +0.96% | Aug 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $26 → $8.6 | Strong Buy → Hold | Downgrades | $26 → $8.6 | +0.96% | Aug 6, 2025 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 5, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $20 → $15 | Buy | Maintains | $20 → $15 | +76.09% | May 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +29.13% | May 19, 2025 |
Financial Forecast
Revenue This Year
84.06M
from 87.69M
Decreased by -4.13%
Revenue Next Year
96.87M
from 84.06M
Increased by 15.23%
EPS This Year
-1.01
from -0.67
EPS Next Year
-1.10
from -1.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 90.3M | 136.3M | 145.2M | ||
| Avg | 84.1M | 96.9M | 109.8M | ||
| Low | 76.5M | 84.2M | 94.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.0% | 62.1% | 49.9% | ||
| Avg | -4.1% | 15.2% | 13.4% | ||
| Low | -12.7% | 0.1% | -2.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.84 | -0.91 | -0.40 | ||
| Avg | -1.01 | -1.10 | -1.09 | ||
| Low | -1.14 | -1.40 | -1.60 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.